Astrazeneca (AZN) Cash & Equivalents (2009 - 2026)

Astrazeneca has reported Cash & Equivalents for 18 years, with the latest figure at $4.9 billion in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 30.67% year-over-year to $4.9 billion in Q2 2026; TTM through Jun 2026 was $4.9 billion, a 30.67% decrease from a year earlier, with the FY2025 full-year figure at $5.7 billion, up 4.06% from the prior year.
• Cash & Equivalents was $4.9 billion for Q2 2026 at Astrazeneca, down from $7.6 billion in the prior quarter.
• The five-year high for Cash & Equivalents was $8.1 billion in Q3 2025, with the low at $4.5 billion in Q3 2022.
• Average Cash & Equivalents over 5 years is $6.0 billion, with a median of $5.7 billion recorded in 2022.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents slumped 69.06% in 2022, then surged 69.75% in 2025.
• Over 5 years, Cash & Equivalents stood at $6.2 billion in 2022, then dropped by 5.29% to $5.8 billion in 2023, then slipped by 6.03% to $5.5 billion in 2024, then advanced by 4.06% to $5.7 billion in 2025, then declined by 14.32% to $4.9 billion in 2026.
• The last three Cash & Equivalents figures came in at $4.9 billion (Q2 2026), $7.6 billion (Q1 2026), and $5.7 billion (Q4 2025), per Business Quant data.